Fig. 8.

CL27c treatment restores normal lung function and improves survival in a moderate model Bleomycin-induced lung fibrosis and dysfunction. a Analysis of the pressure–volume curve in control mice (n = 14) and in mice that developed Bleomycin-induced lung dysfunction after treatment with vehicle (n = 12) or CL27c (n = 12; 2 mg/ml). b Analysis of total lung capacity (TLC) as in A (from left to right n = 4, 4, 5 independent experiments, respectively). c Analysis of inspiratory capacity (IC) as in (a) (from left to right n = 5, 4, 6 independent experiments, respectively). d Measurement of Forced vital capacity (FVC) as in (a) (from left to right n = 5, 4, 6 independent experiments, respectively). e Analysis of forced expiratory volume at 50 millisec (FEV50) as in (a) (from left to right n = 5, 4, 5 independent experiments, respectively). f Quantification of lung resistance (RL) as in (a) (from left to right n = 5, 4, 5 independent experiments, respectively). g Measurement of dynamic compliance (Cdyn) as in (a). h Survival curves of mice treated with either saline (white circles; n = 8) or Bleomycin in the presence (black triangles; n = 10) or absence (black circles; n = 10) of CL27c. Results represent mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001 determined using one-way ANOVA followed by Bonferroni post-hoc test. Animal survival was analyzed by the Mantel–Cox log rank test